Trial Profile

A Phase I Dose-Escalation/Dose Expansion Study Of NBTXR3 Activated By Intensity Modulated Radiation Therapy In Patients With Locally Advanced Squamous Cell Carcinoma Of The Oral Cavity Or Oropharynx

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 15 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Hafnium oxide (Primary) ; Hafnium oxide (Primary)
Indications Carcinoma; Head and neck cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
Focus Adverse reactions; Proof of concept; Therapeutic Use
Acronyms Study 102
Sponsors Nanobiotix

24 Oct 2023 Results of exploratory analysis (n=56) assessing antitumor activity of the radioenhancer NBTXR3 on injected lesions to estimate overall survival presented at the 48th European Society for Medical Oncology Congress
23 Oct 2023 According to a Nanobiotix Media Release, data from this study presented at the 2023 Annual Congress of the European Society for Medical Oncology (ESMO).
23 Oct 2023 Results published in the Nanobiotix Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com